Market Cap 19.18B
Revenue (ttm) 3.12B
Net Income (ttm) 1.14B
EPS (ttm) N/A
PE Ratio 17.50
Forward PE 16.99
Profit Margin 36.44%
Debt to Equity Ratio 0.00
Volume 3,904,600
Avg Vol 2,074,634
Day's Range N/A - N/A
Shares Out 642.06M
Stochastic %K 10%
Beta 0.98
Analysts Strong Sell
Price Target $35.85

Company Profile

Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large Bcell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/...

Industry: Biotechnology
Sector: Healthcare
Phone: 45 70 20 27 28
Address:
Carl Jacobsens Vej 30, Valby, Copenhagen, Denmark
TheRealShortSqueezy
TheRealShortSqueezy Oct. 22 at 2:04 PM
$OSTX Advancing hope in the fight against cancer 🧬 OS Therapies is a clinical-stage biotech company pioneering immunotherapy breakthroughs for osteosarcoma and other solid tumors, bringing new options to patients facing limited treatments. 📰News today: OS Therapies Announces Overall and Event Free Survival Key Subgroup Data for OST-HER2 in Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma With a Final Type C Meeting scheduled with the FDA on December 11, 2025 and a pre-MAA meeting granted by the U.K. MHRA, OS Therapies moves closer to potential regulatory milestones for its OST-HER2 program. 📊Technical view: - Key support $1.X.74 - Key levels on upside breakouts: $1.X.96 ➡️ $2.X.11➡️$2.X.25 ➡️ $2.X.36 ➡️ $2.X.52 News link : https://tinyurl.com/mvp66br5 Communicated Disclaimer: https://stockresearchtoday.com/groundbreaking-treatments-for-solid-tumors/ Sector Peers: $GMAB $AZN $PFE $ABBV
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Oct. 21 at 5:34 PM
@outlawinvestor1 FYI $MRUS filed their 14D9 this morning that includes, among other things, the revenue forecast provided $GMAB as part of the broader financial projections. You were definitely right again. The MRUS forecasts, especially in the later years, are considerably higher than 3 analysts had projected. I prepared a simple comparison of the 2 showing you snapshots as well. We track these for all commercial-stage bios. It's our experience the projections are closer except for BPMC (BPMC's forecasts were much higher than analysts in the later years). I included an updated comparison of the various revenue multiples versus $PTGX as well. For those interested in clinical-stage bios (and commercial-stage for that matter), may I recommend you follow outlawinvestor1 Otherwise FYI only. This is not investment advice. $IBB $IBBQ
0 · Reply
BigManThings12
BigManThings12 Oct. 21 at 12:59 PM
$GMAB why is it going down
0 · Reply
Quantumup
Quantumup Oct. 20 at 7:30 PM
Piper Sandler⬆️ $CRBP's PT to $51 from $35, reiterated at Overweight, and said Data Provides Proof of Efficacy for CRB-701 in HNSCC and Cervical $MRUS - $GMAB $PFE Piper Sandler added:
0 · Reply
SEVENXStheGOAT
SEVENXStheGOAT Oct. 18 at 10:59 AM
$GMAB updated data from the Phase 1/2 RAINFOL-01 trial showed rinatabart sesutecan 100 mg/m2 demonstrated 50% confirmed ORR, including two CRs, regardless of FRα expression. #ESMO25
0 · Reply
Wigglyick
Wigglyick Oct. 17 at 2:15 PM
$GMAB Danish company - Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases.
1 · Reply
jrobbins64
jrobbins64 Oct. 16 at 1:38 PM
$GMAB $50+ after earnings!
0 · Reply
JarvisFlow
JarvisFlow Oct. 15 at 10:29 AM
HC Wainwright & Co. has adjusted their stance on Genmab ( $GMAB ), setting the rating to Buy with a target price of 40.
0 · Reply
Power2k
Power2k Oct. 14 at 3:23 PM
$PYXS $GMAB acquired $MRUS for 8B mostly due to Merus' promising Head & Neck cancer (HNSCC) trial data. Pyxis has a matched or even a bit superior HNSCC data than Merus', and it sits only at 200M cap. Extremely undervalued.
0 · Reply
SheriffGrover
SheriffGrover Oct. 13 at 6:47 AM
$GMAB FYI : https://finance.yahoo.com/news/genmab-rally-justified-strong-quarterly-100809653.html
0 · Reply
Latest News on GMAB
Why Is Genmab Stock Trading Lower On Monday?

Oct 20, 2025, 11:57 AM EDT - 5 days ago

Why Is Genmab Stock Trading Lower On Monday?


Genmab A/S (GMAB) M&A Call Transcript

Sep 29, 2025, 5:47 PM EDT - 26 days ago

Genmab A/S (GMAB) M&A Call Transcript


Genmab to buy Dutch cancer drugmaker Merus for $8 billion

Sep 29, 2025, 1:19 AM EDT - 26 days ago

Genmab to buy Dutch cancer drugmaker Merus for $8 billion

MRUS


Major Shareholder Announcement

Sep 23, 2025, 9:18 AM EDT - 4 weeks ago

Major Shareholder Announcement


Genmab: A Matter Of Time

Sep 12, 2025, 6:15 AM EDT - 6 weeks ago

Genmab: A Matter Of Time


Genmab A/S (GMAB) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 8:18 PM EDT - 2 months ago

Genmab A/S (GMAB) Q2 2025 Earnings Call Transcript


Genmab Announces Financial Results for the First Half of 2025

Aug 7, 2025, 11:08 AM EDT - 2 months ago

Genmab Announces Financial Results for the First Half of 2025


Genmab Announces Changes to its Executive Committee

Jul 1, 2025, 8:00 AM EDT - 4 months ago

Genmab Announces Changes to its Executive Committee


Completion of Share Buy-back Program

Jun 30, 2025, 9:30 AM EDT - 4 months ago

Completion of Share Buy-back Program


Transactions in Connection with Share Buy-back Program

Jun 23, 2025, 8:19 AM EDT - 4 months ago

Transactions in Connection with Share Buy-back Program


Genmab Announces Financial Results for the First Quarter of 2024

May 8, 2025, 11:01 AM EDT - 6 months ago

Genmab Announces Financial Results for the First Quarter of 2024


Genmab's Outlook Beyond Darzalex's Patent Cliff

Apr 15, 2025, 7:36 AM EDT - 6 months ago

Genmab's Outlook Beyond Darzalex's Patent Cliff


Genmab A/S Share Capital Reduction

Apr 10, 2025, 12:20 PM EDT - 7 months ago

Genmab A/S Share Capital Reduction


Transactions In Connection with Share Buy-back Program

Apr 7, 2025, 7:43 AM EDT - 7 months ago

Transactions In Connection with Share Buy-back Program


TheRealShortSqueezy
TheRealShortSqueezy Oct. 22 at 2:04 PM
$OSTX Advancing hope in the fight against cancer 🧬 OS Therapies is a clinical-stage biotech company pioneering immunotherapy breakthroughs for osteosarcoma and other solid tumors, bringing new options to patients facing limited treatments. 📰News today: OS Therapies Announces Overall and Event Free Survival Key Subgroup Data for OST-HER2 in Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma With a Final Type C Meeting scheduled with the FDA on December 11, 2025 and a pre-MAA meeting granted by the U.K. MHRA, OS Therapies moves closer to potential regulatory milestones for its OST-HER2 program. 📊Technical view: - Key support $1.X.74 - Key levels on upside breakouts: $1.X.96 ➡️ $2.X.11➡️$2.X.25 ➡️ $2.X.36 ➡️ $2.X.52 News link : https://tinyurl.com/mvp66br5 Communicated Disclaimer: https://stockresearchtoday.com/groundbreaking-treatments-for-solid-tumors/ Sector Peers: $GMAB $AZN $PFE $ABBV
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Oct. 21 at 5:34 PM
@outlawinvestor1 FYI $MRUS filed their 14D9 this morning that includes, among other things, the revenue forecast provided $GMAB as part of the broader financial projections. You were definitely right again. The MRUS forecasts, especially in the later years, are considerably higher than 3 analysts had projected. I prepared a simple comparison of the 2 showing you snapshots as well. We track these for all commercial-stage bios. It's our experience the projections are closer except for BPMC (BPMC's forecasts were much higher than analysts in the later years). I included an updated comparison of the various revenue multiples versus $PTGX as well. For those interested in clinical-stage bios (and commercial-stage for that matter), may I recommend you follow outlawinvestor1 Otherwise FYI only. This is not investment advice. $IBB $IBBQ
0 · Reply
BigManThings12
BigManThings12 Oct. 21 at 12:59 PM
$GMAB why is it going down
0 · Reply
Quantumup
Quantumup Oct. 20 at 7:30 PM
Piper Sandler⬆️ $CRBP's PT to $51 from $35, reiterated at Overweight, and said Data Provides Proof of Efficacy for CRB-701 in HNSCC and Cervical $MRUS - $GMAB $PFE Piper Sandler added:
0 · Reply
SEVENXStheGOAT
SEVENXStheGOAT Oct. 18 at 10:59 AM
$GMAB updated data from the Phase 1/2 RAINFOL-01 trial showed rinatabart sesutecan 100 mg/m2 demonstrated 50% confirmed ORR, including two CRs, regardless of FRα expression. #ESMO25
0 · Reply
Wigglyick
Wigglyick Oct. 17 at 2:15 PM
$GMAB Danish company - Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases.
1 · Reply
jrobbins64
jrobbins64 Oct. 16 at 1:38 PM
$GMAB $50+ after earnings!
0 · Reply
JarvisFlow
JarvisFlow Oct. 15 at 10:29 AM
HC Wainwright & Co. has adjusted their stance on Genmab ( $GMAB ), setting the rating to Buy with a target price of 40.
0 · Reply
Power2k
Power2k Oct. 14 at 3:23 PM
$PYXS $GMAB acquired $MRUS for 8B mostly due to Merus' promising Head & Neck cancer (HNSCC) trial data. Pyxis has a matched or even a bit superior HNSCC data than Merus', and it sits only at 200M cap. Extremely undervalued.
0 · Reply
SheriffGrover
SheriffGrover Oct. 13 at 6:47 AM
$GMAB FYI : https://finance.yahoo.com/news/genmab-rally-justified-strong-quarterly-100809653.html
0 · Reply
Pika_Capital
Pika_Capital Oct. 11 at 12:02 PM
$PTGX proceeds will be redeployed into $IMVT, $APGE (possibly more $GMAB ) and across bunch of other names in pfolio. May reenter $BHVN again but not sure, it's a lower conviction name going into PDUFa.
2 · Reply
topstockalerts
topstockalerts Oct. 10 at 5:37 PM
Bristol Myers Squibb agreed to acquire Orbital Therapeutics, a private biotech developing RNA-based medicines, for $1.5 billion, extending a wave of major biotech deals this year. Founded in 2022, Orbital raised $270 million in a 2023 Series A round. Its lead candidate, OTX-201, an RNA therapy for autoimmune diseases, is expected to enter human trials in 2026. The deal marks Bristol’s largest since its $4.1 billion purchase of RayzeBio in February 2024. The acquisition spree spans the sector: Novo Nordisk recently announced a $4.7 billion deal for Akero Therapeutics; Pfizer agreed to buy Metsera for $4.9 billion; and Genmab unveiled an $ 8 billion purchase of Merus. Meanwhile, Johnson & Johnson is reportedly in talks to acquire Protagonist Therapeutics, whose psoriasis drug is being developed with J&J. Analysts say the surge reflects Big Pharma’s race to rebuild pipelines as patents expire. $BMY $PFE $GMAB $JNJ
0 · Reply
Zakk5150
Zakk5150 Oct. 9 at 8:57 PM
$GMAB now I’m really mad 🤣.
0 · Reply
Zakk5150
Zakk5150 Oct. 9 at 5:23 PM
$GMAB the fact I can’t get outta this dumbass position is insane . Valued at 50 can’t even sell the shit
0 · Reply
JarvisFlow
JarvisFlow Oct. 8 at 3:38 PM
HC Wainwright & Co. has updated their rating for Genmab ( $GMAB ) to Buy with a price target of 35.
0 · Reply
jrobbins64
jrobbins64 Oct. 7 at 2:18 PM
$GMAB Earnings coming soon should continue the rise!
0 · Reply
txbondman
txbondman Oct. 7 at 3:17 AM
sld some winners (partial) to take profits. sld $AAON for a 30% gain; sld $ASML for a 60% gain; sld $GMAB for a 15% gain; sld $LRCX for a 500% gain
0 · Reply
ZacksResearch
ZacksResearch Oct. 6 at 3:00 PM
$GMAB spikes 21.9% after announcing $8B acquisition of $MRUS! Strategic acquisition to expand GMAB's oncology pipeline, adding Merus' promising late-stage candidate, petosemtamab. Petosemtamab has FDA Breakthrough Therapy designations and impressive phase II results, supporting GMAB's long-term growth strategy. Discover why GMAB could be a biotech leader 👉 https://www.zacks.com/stock/news/2762765/gmab-stock-soars-219-in-a-month-following-mrus-acquisition-deal?cid=sm-stocktwits-2-2762765-body-14729&ADID=SYND_STOCKTWITS_TWEET_2_2762765_BODY_14729
0 · Reply
ZacksResearch
ZacksResearch Oct. 6 at 1:38 PM
$GMAB up nearly 22% in a month — here’s why the rally’s catching fire Genmab just sealed an $8B acquisition of Merus, bringing in a late-stage cancer treatment candidate to strengthen its oncology pipeline — a clear strategic move fueling the surge. Full story on the deal’s impact here 👉 https://www.zacks.com/stock/news/2762765/gmab-stock-soars-219-in-a-month-following-mrus-acquisition-deal?cid=sm-stocktwits-2-2762765-teaser-14722&ADID=SYND_STOCKTWITS_TWEET_2_2762765_TEASER_14722
0 · Reply
CDMO
CDMO Oct. 3 at 3:04 PM
$GMAB it did nothing for months and now its up up up up. Maybe merus acquisition is liked by people. I think it is a too big for them and i am skeptical tbh. Brings a lot of cash burn
1 · Reply
stockpicker63
stockpicker63 Oct. 3 at 2:25 PM
$GMAB Free tip nice profit above +8%
0 · Reply
JarvisFlow
JarvisFlow Oct. 2 at 2:03 PM
HC Wainwright & Co. has updated their rating for Genmab ( $GMAB ) to Buy with a price target of 40.
0 · Reply